Table 2.
Active Trials Open to Metaplastic Breast Cancer Patients
| Targeted Therapies | Phase | ||
|---|---|---|---|
| ARQule | ARQ751 (pan-AKT inhibitor) with fulvestrant or paclitaxel in patients with PIK3CA/AKT/PTEN mutations | NCT02761694 | Ib |
| ARTEMIS | A Robust TNBC Evaluation Framework to Improve Survival- molecular profiling of treatment naïve tumour while patient undergoes NACT; targeted therapy trials recommended where appropriate | NCT02276443 | Ib/II |
| L-NMMA | Pan-nitric oxide synthase inhibitor plus docetaxel in advanced or metastatic TNBC patients | NCT02834403 | Ib/II |
| Women’s MoonShot | Neoadjuvant Treatment with PaCT (panitumumab (anti-EGFR) carboplatin and paclitaxel) for Patients With Locally Advanced TNBC | NCT02593175 | II |
| Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I–III Androgen Receptor-Positive TNBC | NCT02689427 | IIb | |
| Liposomal Doxorubicin, Bevacizumab (anti-VEGF), and Everolimus (mTOR inhibitor) in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | NCT02456857 | II | |
| Immunotherapies | Phase | ||
| DART | Dual anti-CTLA4 (nivolumab) and anti-PD1 (ipilimumab) blockade | NCT02834013 | II |
| Morpheus-TNBC | Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced TNBC | NCT03424005 | Ib/II |
| SWOG S1418 | Pembrolizumab (anti-PD1) as adjuvant therapy for TNBC after neoadjuvant therapy | NCT02954874 | III |
| Pembrolizumab (anti-PD1) plus nab-paclitaxel for TNBC and HR+/HER2− breast cancer | NCT02752685 | II | |
| TN First-Line | Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With TNBC | NCT02530489 | II |
| PAveMenT | Palbociclib and Avelumab in Metastatic AR+ TNBC | NCT04360941 | Ib |